Want to join the conversation?
Focus Diagnostics, the products business of $DGX, received FDA 501(k) clearance for its Simplexa Flu A/B & RSV Direct Kit. The kit can detect 46 additional influenza A/B strains and seven additional RSV strains. The approval increases the number of flu and RSV strains that Simplexa can detect to 92, the most for any FDA-cleared molecular test kit.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?